Clinical Trial Update: Tepotinib in Solid Tumors Harboring MET Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial update for tepotinib in solid tumors with MET alterations, including MET exon 14 skipping and MET amplification.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Tepotinib (tepotinib)

Snippet

Sponsor: Chungbuk National University Hospital | Conditions: Solid Tumor, MET Exon 14 Skipping Mutation | Phase 2 | Status: UNKNOWN